2017
CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus–Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC)
Trickey A, May MT, Schommers P, Tate J, Ingle SM, Guest JL, Gill MJ, Zangerle R, Saag M, Reiss P, Monforte A, Johnson M, Lima VD, Sterling TR, Cavassini M, Wittkop L, Costagliola D, Sterne JAC, Boulle A, Stephan C, Miro J, Cavassini M, Chêne G, Costagliola D, Dabis F, Monforte A, del Amo J, Van Sighem A, Vehreschild J, Gill J, Guest J, Haerry D, Hogg R, Justice A, Shepherd L, Obel N, Crane H, Smith C, Reiss P, Saag M, Sterling T, Teira R, Williams M, Zangerle R, Sterne J, May M, Ingle S, Trickey A. CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus–Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC). Clinical Infectious Diseases 2017, 65: 959-966. PMID: 28903507, PMCID: PMC5850630, DOI: 10.1093/cid/cix466.Peer-Reviewed Original ResearchConceptsAdjusted hazard ratioCD8 countsCD8 ratioCohort CollaborationAntiretroviral therapyCause mortalityCD4 countHazard ratioMiddle tertilePrognostic markerAIDS mortalityCause-specific mortality hazard ratiosAntiretroviral Therapy Cohort CollaborationHigher CD4 countsMortality hazard ratioCells/μLHuman immunodeficiency virusIndependent prognostic markerNorth American cohortAssociation of CD8Shape of associationsAssociation of CD4Immunodeficiency virusHuman immunodeficiencyCD4
2016
Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study
May MT, Vehreschild JJ, Trickey A, Obel N, Reiss P, Bonnet F, Mary-Krause M, Samji H, Cavassini M, Gill MJ, Shepherd LC, Crane HM, Monforte A, Burkholder GA, Johnson MM, Sobrino-Vegas P, Domingo P, Zangerle R, Justice AC, Sterling TR, Miró JM, Sterne JAC, Collaboration F, Boulle A, Stephan C, Miro J, Cavassini M, Chêne G, Costagliola D, Dabis F, Monforte A, del Amo J, Van Sighem A, Fätkenheuer G, Gill J, Guest J, Haerry D, Hogg R, Justice A, Shepherd L, Obel N, Crane H, Smith C, Reiss P, Saag M, Sterling T, Teira R, Williams M, Zangerle R, Sterne J, May M, Ingle S, Trickey A. Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study. Clinical Infectious Diseases 2016, 62: 1571-1577. PMID: 27025828, PMCID: PMC4885653, DOI: 10.1093/cid/ciw183.Peer-Reviewed Original ResearchConceptsStart of ARTMortality rate ratiosCombination antiretroviral therapyAntiretroviral therapyMortality of patientsCD4 countMortality rateLow baseline CD4 countYears of ARTBaseline CD4 countHigher baseline CD4Collaborative Cohort StudyStart of treatmentNorth American cohortStrong inverse associationLong-term survivalShort-term survivalBaseline CD4CD4 groupCohort studyInverse associationPatientsAmerican cohortYears durationMortality
2015
Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals
May MT, Justice AC, Birnie K, Ingle SM, Smit C, Smith C, Neau D, Guiguet M, Schwarze-Zander C, Moreno S, Guest JL, Monforte A, Tural C, Gill MJ, Bregenzer A, Kirk O, Saag M, Sterling TR, Crane HM, Sterne JA. Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2015, 69: 348-354. PMID: 25848927, PMCID: PMC4506784, DOI: 10.1097/qai.0000000000000603.Peer-Reviewed Original ResearchConceptsInjection drug useDrug useLiver-related mortalityHepatitis C infectionEffect of HCVMortality hazard ratioNorth American cohortHCV coinfectionHCV statusAntiretroviral therapyC infectionHepatitis CHazard ratioSurvival differencesRisk factorsExcess mortalityPoor survivalRisk groupsHCVAmerican cohortHIVNew treatmentsMortalitySubstantial proportionComplete dataSmoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America
Helleberg M, May MT, Ingle SM, Dabis F, Reiss P, Fätkenheuer G, Costagliola D, d’Arminio A, Cavassini M, Smith C, Justice AC, Gill J, Sterne JA, Obel N. Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America. AIDS 2015, 29: 221-229. PMID: 25426809, PMCID: PMC4284008, DOI: 10.1097/qad.0000000000000540.Peer-Reviewed Original ResearchConceptsMortality rate ratiosCardiovascular diseaseLife expectancyBackground populationNon-AIDS malignanciesAntiretroviral therapy initiationProportion of smokersNorth American cohortSmoking-related mortalityCause of deathMore life yearsAIDS malignanciesAntiretroviral therapyPrevious smokersTherapy initiationSmoking cessationSmoking increasesExcess mortalityAge 35HIVSmokersAmerican cohortSmokingLife yearsHigh mortality
2014
Mortality in Patients with HIV-1 Infection Starting Antiretroviral Therapy in South Africa, Europe, or North America: A Collaborative Analysis of Prospective Studies
Boulle A, Schomaker M, May MT, Hogg RS, Shepherd BE, Monge S, Keiser O, Lampe FC, Giddy J, Ndirangu J, Garone D, Fox M, Ingle SM, Reiss P, Dabis F, Costagliola D, Castagna A, Ehren K, Campbell C, Gill MJ, Saag M, Justice AC, Guest J, Crane HM, Egger M, Sterne JA. Mortality in Patients with HIV-1 Infection Starting Antiretroviral Therapy in South Africa, Europe, or North America: A Collaborative Analysis of Prospective Studies. PLOS Medicine 2014, 11: e1001718. PMID: 25203931, PMCID: PMC4159124, DOI: 10.1371/journal.pmed.1001718.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyHigh early mortalityEarly mortalityMortality rateAdjusted mortality rate ratioCumulative mortalityDeath registry linkageHIV-1 infectionMortality rate ratiosNorth American cohortSouth African cohortAdvanced diseaseCD4 countRegistry linkageProspective studyVital statusHIV treatmentEuropean cohortPoor ascertainmentHIV-1African cohortAmerican cohortPatientsMortalityCohort